Search hospitals > New York > New York

NYU School of Medicine's Kaplan Comprehensive Cancer Center

Claim this profile
New York, New York 10016
Global Leader in Breast Cancer
Global Leader in Ovarian Cancer
Conducts research for Brain Tumor
Conducts research for Lymphoma
Conducts research for Lung Cancer
273 reported clinical trials
6 medical researchers
Photo of NYU School of Medicine's Kaplan Comprehensive Cancer Center in New YorkPhoto of NYU School of Medicine's Kaplan Comprehensive Cancer Center in New YorkPhoto of NYU School of Medicine's Kaplan Comprehensive Cancer Center in New York

Summary

NYU School of Medicine's Kaplan Comprehensive Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Breast Cancer, Ovarian Cancer, Brain Tumor, Lymphoma, Lung Cancer and other specialties. NYU School of Medicine's Kaplan Comprehensive Cancer Center is involved with conducting 273 clinical trials across 223 conditions. There are 6 research doctors associated with this hospital, such as Paul Oberstein, MD, Janice M. Mehnert, Kristen Spencer, MD, and Elaine Shum, MD.

Area of expertise

1Breast Cancer
Global Leader
NYU School of Medicine's Kaplan Comprehensive Cancer Center has run 33 trials for Breast Cancer. Some of their research focus areas include:
ER positive
Stage IV
PR positive
2Ovarian Cancer
Global Leader
NYU School of Medicine's Kaplan Comprehensive Cancer Center has run 28 trials for Ovarian Cancer. Some of their research focus areas include:
Stage III
Stage IV
HER2 positive

Top PIs

Clinical Trials running at NYU School of Medicine's Kaplan Comprehensive Cancer Center

Lung Cancer
Non-Small Cell Lung Cancer
Skin Cancer
Breast Cancer
Cancer
Microsatellite Instability
Bladder Cancer
Pancreatic Cancer
Usher syndrome
Small Cell Lung Cancer
Image of trial facility.

REGN5093

for Lung Cancer

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
Recruiting1 award Phase 1 & 25 criteria
Image of trial facility.

Biomarker Screening

for Lung Cancer

RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer. PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.
Recruiting1 award N/A10 criteria
Image of trial facility.

Divarasib + Pembrolizumab

for Non-Small Cell Lung Cancer

This trial is testing a new drug called divarasib along with other cancer treatments. It focuses on people with advanced or metastatic non-small cell lung cancer. The study aims to see how divarasib moves through the body, its safety, and if it helps fight the cancer.
Recruiting1 award Phase 1 & 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at NYU School of Medicine's Kaplan Comprehensive Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security